Kow CS, Ramachandram DS, Hasan SS (2022) The effect of higher-intensity dosing of anticoagulation on the clinical outcomes in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials. J Infect Chemother 28(2):257–265. https://doi.org/10.1016/j.jiac.2021.11.008

Article  CAS  PubMed  Google Scholar 

Sholzberg M, Tang GH, Rahhal H, AlHamzah M, Kreuziger LB, Áinle FN, Alomran F, Alayed K, Alsheef M, AlSumait F et al (2021) Effectiveness of therapeutic heparin versus prophylactic heparin on death, mechanical ventilation, or intensive care unit admission in moderately ill patients with covid-19 admitted to hospital: RAPID randomised clinical trial. BMJ 375:n2400. https://doi.org/10.1136/bmj.n2400

Article  PubMed  Google Scholar 

Investigators REMAP-CAP, Investigators ACTIV-4a, Investigators ATTACC, Lawler PR, Goligher EC, Berger JS, Neal MD, McVerry BJ, Nicolau JC, Gong MN et al (2021) Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19. N Engl J Med 385:790–802. https://doi.org/10.1056/NEJMoa2105911

Article  Google Scholar 

Zuily S, Lefèvre B, Sanchez O, Empis de Vendin O, de Ciancio G, Arlet JB, Khider L, Terriat B, Greigert H, Robert CS et al (2023) Effect of weight-adjusted intermediate-dose versus fixed-dose prophylactic anticoagulation with low-molecular-weight heparin on venous thromboembolism among noncritically and critically ill patients with COVID-19: the COVI-DOSE trial, a multicenter, randomised, open-label, phase 4 trial. EClinicalMedicine 60:102031. https://doi.org/10.1016/j.eclinm.2023.102031

Article  PubMed  PubMed Central  Google Scholar 

Dixon B, Smith RJ, Campbell DJ, Moran JL, Doig GS, Rechnitzer T, MacIsaac CM, Simpson N, van Haren FMP, Ghosh AN et al (2021) Nebulised heparin for patients with or at risk of acute respiratory distress syndrome: a multicentre, randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med 9:360–372. https://doi.org/10.1016/S2213-2600(20)30470-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu X, Xiang M, Jing H, Liu L, Wang C, Novakovic VA, Shi J (2023) Early antithrombotic therapy for another highly lethal viral pneumonia pandemic. Clin Microbiol Infect 29(3):284–287. https://doi.org/10.1016/j.cmi.2022.11.008

Article  CAS  PubMed  Google Scholar 

Duijvelaar E, Schippers JR, Smeele PJ, de Raaf MA, Vanhove ALEM, Blok SG, Counter COVID Collaborative Group, Twisk JWR, Vonk Noordegraaf A, de Man FS et al (2022) Long-term clinical outcomes of COVID-19 patients treated with imatinib. Lancet Respir Med 10(4):e34–e35. https://doi.org/10.1016/S2213-2600(22)00052-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Atmowihardjo LN, Schippers JR, Duijvelaar E, Bartelink IH, Bet PM, Swart NEL, van Rein N, Purdy K, Cavalla D, McElroy A et al (2023) Efficacy and safety of intravenous imatinib in COVID-19 ARDS: a randomized, double-blind, placebo-controlled clinical trial. Crit Care 27(1):226. https://doi.org/10.1186/s13054-023-04516-4

Article  PubMed  PubMed Central  Google Scholar 

Morales-Ortega A, Farfán-Sedano AI, San Martín-López JV, Escribá-Bárcena A, Jaenes-Barrios B, Madroñal-Cerezo E, Llarena-Barroso C, Mesa-Plaza N, Frutos-Pérez B, Ruiz-Giardín JM et al (2023) Baricitinib or imatinib in hospitalized COVID-19 patients: results from COVINIB, an exploratory randomized clinical trial. J Med Virol 95(2):e28495. https://doi.org/10.1002/jmv.28495

Article  CAS  PubMed  Google Scholar